Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.56 |
| ▸ | STAT1 | P42224 | 3/20 | 0.53 |
| ▸ | STAT3 | P40763 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18810466 | 0.95 | S1PR3 (0.58) | SMN1; SMN2LMNAPOLBS1PR3STAT1 | |
| SCHEMBL15599243 | 0.95 | S1PR3 (0.58) | SMN1; SMN2LMNAPOLBS1PR3STAT1 | |
| SCHEMBL20305303 | 0.93 | SMN1; SMN2 (0.65) | SMN1; SMN2LMNAPOLBS1PR3STAT1 | |
| SCHEMBL21679038 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAPOLBS1PR3STAT1 | |
| SCHEMBL21679155 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAPOLBS1PR3STAT1 | |
| SCHEMBL892519 | 0.80 | HSD17B10 (0.53) | SMN1; SMN2LMNAPOLBS1PR3RAB9A | |
| SCHEMBL31644564 | 0.80 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAPOLBSTAT1STAT3 | |
| SCHEMBL22554186 | 0.80 | S1PR3 (0.62) | POLBS1PR3STAT1STAT3ALDH1A1 | |
| SCHEMBL891991 | 0.79 | S1PR3 (0.55) | SMN1; SMN2LMNAPOLBS1PR3RAB9A | |
| SCHEMBL17619253 | 0.78 | S1PR3 (0.60) | SMN1; SMN2S1PR3STAT1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-112088157-B | Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors | 拉文纳制药公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-112088157-A | Aryl-bipyridine amine derivatives as phosphoinositide kinase inhibitors | 拉文纳制药公司 | 2020-12-15 | — | — | CN | disclosed |
| EP-3728230-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1A, PIP5K1B, PIP5K1C | SMN1; SMN2 3679/4885LMNA 3441/4885POLB 2076/4885 |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PIP5K1C | SMN1; SMN2 3679/4885LMNA 3441/4885POLB 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.